West Pharmaceutical Company Insiders
WST Stock | USD 336.34 0.86 0.26% |
West Pharmaceutical's insiders are aggressively selling. The analysis of insiders' sentiment of trading West Pharmaceutical Services stock suggests that vertually all insiders are panicking at this time. West Pharmaceutical employs about 10.6 K people. The company is managed by 34 executives with a total tenure of roughly 212 years, averaging almost 6.0 years of service per executive, having 311.76 employees per reported executive.
Eric Green CEO President, Chief Executive Officer, Director |
Patrick Zenner Chairman Independent Chairman of the Board |
West Pharmaceutical's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-11-08 | Jared Moskowitz | Disposed @ 323.9 | |||
2024-10-29 | Charles Witherspoon | Disposed 703 @ 310.4 | View | ||
2024-08-19 | Charles Witherspoon | Disposed 1029 @ 300 | View | ||
2024-06-12 | Silji Abraham | Disposed 1800 @ 330.78 | View | ||
2024-05-10 | Thomas W Hofmann | Disposed 617 @ 365.92 | View | ||
2024-05-07 | Eric Mark Green | Disposed 66000 @ 366.65 | View | ||
2024-03-11 | Chad Winters | Disposed 815 @ 358.82 | View | ||
2024-02-28 | Charles Witherspoon | Disposed 2019 @ 358.62 | View | ||
2024-02-27 | Eric Mark Green | Disposed 64132 @ 359.85 | View | ||
2024-02-23 | Silji Abraham | Disposed 7012 @ 365 | View |
Monitoring West Pharmaceutical's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
West |
West Pharmaceutical's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with West Pharmaceutical's future performance. Based on our forecasts, it is anticipated that West will maintain a workforce of slightly above 10600 employees by February 2025.West Pharmaceutical's latest congressional trading
Congressional trading in companies like West Pharmaceutical, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in West Pharmaceutical by those in governmental positions are based on the same information available to the general public.
2024-12-09 | Representative Jared Moskowitz | Acquired Under $15K | Verify | ||
2024-10-08 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
2024-08-21 | Representative Jared Moskowitz | Acquired Under $15K | Verify | ||
2020-10-19 | Representative Greg Gianforte | Acquired $50K to $100K | Verify |
West Pharmaceutical Management Team Effectiveness
The company has Return on Asset of 0.1 % which means that on every $100 spent on assets, it made $0.1 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1778 %, implying that it generated $0.1778 on every 100 dollars invested. West Pharmaceutical's management efficiency ratios could be used to measure how well West Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. At this time, West Pharmaceutical's Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.15 in 2025, whereas Return On Capital Employed is likely to drop 0.10 in 2025. At this time, West Pharmaceutical's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 4.6 B in 2025, whereas Non Current Liabilities Total is likely to drop slightly above 307.8 M in 2025.Net Income Applicable To Common Shares is likely to gain to about 707.5 M in 2025, whereas Common Stock Shares Outstanding is likely to drop slightly above 74.7 M in 2025.
West Pharmaceutical Workforce Comparison
West Pharmaceutical Services is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 230,680. West Pharmaceutical holds roughly 10,600 in number of employees claiming about 5% of equities under Health Care industry.
West Pharmaceutical Profit Margins
The company has Net Profit Margin of 0.17 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.22 %, which entails that for every 100 dollars of revenue, it generated $0.22 of operating income.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.26 | 0.34 |
|
| |||||
Net Profit Margin | 0.19 | 0.18 |
|
| |||||
Operating Profit Margin | 0.22 | 0.21 |
|
| |||||
Pretax Profit Margin | 0.22 | 0.21 |
|
| |||||
Return On Assets | 0.15 | 0.14 |
|
| |||||
Return On Equity | 0.096 | 0.19 |
|
|
West Pharmaceutical Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific West Pharmaceutical insiders, such as employees or executives, is commonly permitted as long as it does not rely on West Pharmaceutical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, West Pharmaceutical insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 0.6 | 3 | 5 | 1,360 | 1,819 |
2024-09-01 | 0.5 | 3 | 6 | 37,261 | 69,022 |
2024-06-01 | 1.75 | 14 | 8 | 80,640 | 134,101 |
2024-03-01 | 2.4444 | 22 | 9 | 140,246 | 156,816 |
2023-12-01 | 0.5 | 6 | 12 | 2,784 | 16,384 |
2023-09-01 | 0.4286 | 15 | 35 | 108,752 | 211,504 |
2023-06-01 | 0.7895 | 15 | 19 | 79,064 | 141,030 |
2023-03-01 | 2.2222 | 20 | 9 | 131,867 | 99,436 |
2022-12-01 | 0.25 | 2 | 8 | 50,096 | 94,047 |
2022-09-01 | 0.6667 | 2 | 3 | 545.00 | 6,474 |
2022-06-01 | 6.0 | 12 | 2 | 7,180 | 956.00 |
2022-03-01 | 1.2941 | 22 | 17 | 103,073 | 22,952 |
2021-12-01 | 1.0 | 2 | 2 | 96.00 | 2,407 |
2021-09-01 | 0.625 | 5 | 8 | 10,061 | 31,481 |
2021-06-01 | 2.5 | 10 | 4 | 5,469 | 3,581 |
2021-03-01 | 2.2857 | 16 | 7 | 109,713 | 9,382 |
2020-12-01 | 0.5714 | 4 | 7 | 11,542 | 20,703 |
2020-09-01 | 0.4444 | 4 | 9 | 19,286 | 36,931 |
2020-06-01 | 0.9412 | 16 | 17 | 26,017 | 37,065 |
2020-03-01 | 2.8333 | 17 | 6 | 118,350 | 6,313 |
2019-12-01 | 0.3333 | 1 | 3 | 150.00 | 8,415 |
2019-09-01 | 0.5 | 1 | 2 | 159.00 | 67.00 |
2019-06-01 | 4.0 | 12 | 3 | 19,217 | 9,626 |
2019-03-01 | 5.75 | 23 | 4 | 184,407 | 9,289 |
2018-09-01 | 1.5 | 6 | 4 | 21,083 | 40,916 |
2018-06-01 | 2.5 | 20 | 8 | 176,294 | 242,687 |
2018-03-01 | 22.0 | 22 | 1 | 216,874 | 5,576 |
2017-12-01 | 5.0 | 20 | 4 | 1,756 | 24,610 |
2017-06-01 | 3.8 | 19 | 5 | 77,587 | 118,240 |
2017-03-01 | 12.0 | 24 | 2 | 200,971 | 8,758 |
2016-12-01 | 7.5 | 30 | 4 | 1,794 | 5,796 |
2016-09-01 | 9.5 | 19 | 2 | 14,765 | 17,623 |
2016-06-01 | 5.6667 | 17 | 3 | 23,874 | 10,366 |
2016-03-01 | 1.4333 | 43 | 30 | 463,061 | 173,744 |
2015-12-01 | 2.4167 | 29 | 12 | 104,289 | 106,572 |
2015-09-01 | 1.3333 | 4 | 3 | 53,414 | 109,356 |
2015-06-01 | 2.0 | 26 | 13 | 682,270 | 72,364 |
2015-03-01 | 1.3636 | 45 | 33 | 423,519 | 221,354 |
2014-12-01 | 1.2222 | 22 | 18 | 40,258 | 125,812 |
2014-09-01 | 0.76 | 19 | 25 | 109,206 | 232,432 |
2014-06-01 | 5.0 | 20 | 4 | 53,932 | 49,656 |
2014-03-01 | 1.9545 | 43 | 22 | 497,195 | 156,016 |
2013-12-01 | 1.0769 | 28 | 26 | 102,225 | 277,685 |
2013-09-01 | 1.0 | 22 | 22 | 49,808 | 122,991 |
2013-06-01 | 1.1905 | 25 | 21 | 241,689 | 425,565 |
2013-03-01 | 2.2273 | 49 | 22 | 452,805 | 75,323 |
2012-12-01 | 1.2174 | 28 | 23 | 253,939 | 457,492 |
2012-09-01 | 5.5 | 11 | 2 | 18,177 | 1,500 |
2012-06-01 | 1.375 | 11 | 8 | 170,724 | 268,009 |
2012-03-01 | 3.0 | 21 | 7 | 272,287 | 9,500 |
2011-09-01 | 2.5 | 10 | 4 | 4,237 | 9,290 |
2011-06-01 | 1.5385 | 20 | 13 | 169,351 | 266,330 |
2011-03-01 | 2.875 | 23 | 8 | 371,451 | 207,927 |
2010-09-01 | 3.6667 | 11 | 3 | 8,537 | 11,200 |
2010-06-01 | 2.75 | 11 | 4 | 20,284 | 7,438 |
2010-03-01 | 1.5714 | 22 | 14 | 366,942 | 136,394 |
2009-12-01 | 1.4286 | 10 | 7 | 31,601 | 52,231 |
2009-09-01 | 0.4091 | 9 | 22 | 84,599 | 156,709 |
2009-06-01 | 3.3333 | 10 | 3 | 21,473 | 15,380 |
2009-03-01 | 2.6429 | 37 | 14 | 287,331 | 50,012 |
2008-12-01 | 4.8 | 24 | 5 | 1,423 | 2,829 |
2008-09-01 | 1.7333 | 26 | 15 | 50,472 | 61,313 |
2008-06-01 | 1.7368 | 33 | 19 | 28,457 | 56,254 |
2008-03-01 | 4.0 | 48 | 12 | 315,005 | 136,096 |
2007-12-01 | 5.6 | 28 | 5 | 3,668 | 11,000 |
2005-09-01 | 3.5 | 7 | 2 | 6,074 | 8,601 |
2005-06-01 | 7.0 | 7 | 1 | 2,076 | 2,000 |
West Pharmaceutical Notable Stakeholders
A West Pharmaceutical stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as West Pharmaceutical often face trade-offs trying to please all of them. West Pharmaceutical's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting West Pharmaceutical's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Eric Green | President, Chief Executive Officer, Director | Profile | |
Patrick Zenner | Independent Chairman of the Board | Profile | |
Bernard Birkett | Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer | Profile | |
Aileen RuffPatry | President Manufacturing | Profile | |
Don OCallaghan | President Devices | Profile | |
Annette Favorite | Chief Human Resource Officer, Senior Vice President | Profile | |
Silji Abraham | Senior Vice President and Chief Digital and Transformation Officer | Profile | |
David Montecalvo | Senior Vice President, Chief Operating and Supply Chain Officer | Profile | |
Christopher Ryan | Senior Vice President of Commercial Products and Emerging Markets | Profile | |
Quintin Lai | Vice President - Corporate Development, Strategy and Investor Relations | Profile | |
Andy Polywacz | President Systems | Profile | |
George Miller | Senior Vice President General Counsel, Corporate Secretary | Profile | |
Chad Winters | Chief Accounting Officer, Principal Accounting Officer, Vice President, Corporate Controller | Profile | |
Eric Resnick | Chief Technology Officer, Vice President | Profile | |
Mark Buthman | Independent Director | Profile | |
Deborah Tanner | Independent Director | Profile | |
William Feehery | Independent Director | Profile | |
Robert Friel | Independent Director | Profile | |
Myla LaiGoldman | Independent Director | Profile | |
Paula Johnson | Independent Director | Profile | |
Douglas Michels | Independent Director | Profile | |
Paolo Pucci | Independent Director | Profile | |
Thomas Hofmann | Independent Director | Profile | |
Charles CPA | VP Treasurer | Profile | |
John CFA | Head Relations | Profile | |
Rudy Poussot | Senior Development | Profile | |
Kathy DePadua | Senior Officer | Profile | |
Dr CFA | Vice Relations | Profile | |
Richard Luzzi | VP HR | Profile | |
Michele Polinsky | Vice Communications | Profile | |
Kimberly MacKay | Senior Vice President General Counsel, Corporate Secretary | Profile | |
Molly Joseph | Director | Profile | |
Cindy ReissClark | Senior Vice President of Global Market Units and Commercial Solutions | Profile | |
Robert Segura | VP Devel | Profile |
About West Pharmaceutical Management Performance
The success or failure of an entity such as West Pharmaceutical often depends on how effective the management is. West Pharmaceutical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of West management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the West management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.14 | 0.15 | |
Return On Capital Employed | 0.19 | 0.10 | |
Return On Assets | 0.14 | 0.15 | |
Return On Equity | 0.19 | 0.10 |
Please note, the imprecision that can be found in West Pharmaceutical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of West Pharmaceutical Services. Check West Pharmaceutical's Beneish M Score to see the likelihood of West Pharmaceutical's management manipulating its earnings.
West Pharmaceutical Workforce Analysis
Traditionally, organizations such as West Pharmaceutical use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare West Pharmaceutical within its industry.West Pharmaceutical Manpower Efficiency
Return on West Pharmaceutical Manpower
Revenue Per Employee | 278.3K | |
Revenue Per Executive | 86.8M | |
Net Income Per Employee | 56K | |
Net Income Per Executive | 17.5M | |
Working Capital Per Employee | 119.3K | |
Working Capital Per Executive | 37.2M |
Additional Tools for West Stock Analysis
When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.